{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:10:31Z","timestamp":1787062231500,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Myeloproliferative neoplasms (MPNs) lie at the intersection of malignancy and chronic inflammatory disease. This review summarizes current understanding of how inflammation drives MPN pathogenesis, from clonal initiation to progression and symptom burden, and explores how emerging therapies modulate the inflammatory microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Evidence from human genetics, epidemiology, and experimental models shows that chronic inflammatory stress promotes the expansion of JAK2- and other MPN-associated clones. Inflammatory cytokine networks sustain myeloproliferation, reshape the bone marrow niche, and contribute to fibrosis. JAK inhibitors remain the cornerstone of therapy and exert much of their clinical benefit through suppression of cytokine signaling. Newer agents also mitigate inflammation through complementary mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Inflammation is inseparable from MPN biology and represents both a driver and a therapeutic target. Reframing MPN as a disorder of maladaptive immune and stromal interactions highlights opportunities to restore balance within this ecosystem and potentially alter disease course.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11899-026-00774-5","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:58:45Z","timestamp":1772787525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes"],"prefix":"10.1007","volume":"21","author":[{"given":"Angela G","family":"Fleischman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"5","key":"774_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1182\/blood-2017-06-746412","volume":"131","author":"G de Haan","year":"2018","unstructured":"de Haan G, Lazare SS. Aging of hematopoietic stem cells. Blood. 2018;131(5):479\u201387.","journal-title":"Blood"},{"issue":"9","key":"774_CR2","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.4049\/jimmunol.1003438","volume":"186","author":"BL Esplin","year":"2011","unstructured":"Esplin BL, Shimazu T, Welner RS, Garrett KP, Nie L, Zhang Q, et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol (Baltimore Md: 1950). 2011;186(9):5367\u201375.","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"774_CR3","doi-asserted-by":"crossref","unstructured":"Caiado F, Pietras EM, Manz MG. Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. J Exp Med. 2021;218(7):e20201541.","DOI":"10.1084\/jem.20201541"},{"issue":"3","key":"774_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s40778-020-00177-z","volume":"6","author":"D Hormaechea-Agulla","year":"2020","unstructured":"Hormaechea-Agulla D, Le DT, King KY. Common sources of inflammation and their impact on hematopoietic stem cell biology. Curr Stem Cell Rep. 2020;6(3):96\u2013107.","journal-title":"Curr Stem Cell Rep"},{"issue":"21","key":"774_CR5","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","volume":"29","author":"SY Kristinsson","year":"2011","unstructured":"Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf AR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncology: Official J Am Soc Clin Oncol. 2011;29(21):2897\u2013903.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"7","key":"774_CR6","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","volume":"95","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216\u201320.","journal-title":"Haematologica"},{"issue":"6","key":"774_CR7","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","volume":"112","author":"O Landgren","year":"2008","unstructured":"Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199\u2013204.","journal-title":"Blood"},{"issue":"8","key":"774_CR8","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","volume":"128","author":"DA Hinds","year":"2016","unstructured":"Hinds DA, Barnholt KE, Mesa RA, Kiefer AK, Do CB, Eriksson N, et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood. 2016;128(8):1121\u20138.","journal-title":"Blood"},{"key":"774_CR9","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.1038\/ncomms7691","volume":"6","author":"W Tapper","year":"2015","unstructured":"Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015;6:6691.","journal-title":"Nat Commun"},{"issue":"2","key":"774_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","volume":"141","author":"AG Bick","year":"2020","unstructured":"Bick AG, Pirruccello JP, Griffin GK, Gupta N, Gabriel S, Saleheen D, et al. Genetic Interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation. 2020;141(2):124\u201331.","journal-title":"Circulation"},{"issue":"4","key":"774_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1161\/CIRCULATIONAHA.122.062126","volume":"147","author":"C Vlasschaert","year":"2023","unstructured":"Vlasschaert C, Heimlich JB, Rauh MJ, Natarajan P, Bick AG. Interleukin-6 receptor polymorphism attenuates clonal Hematopoiesis-Mediated coronary artery disease risk among 451 180 individuals in the UK biobank. Circulation. 2023;147(4):358\u201360.","journal-title":"Circulation"},{"issue":"2","key":"774_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/bloodadvances.2018026450","volume":"3","author":"HY Lai","year":"2019","unstructured":"Lai HY, Brooks SA, Craver BM, Morse SJ, Nguyen TK, Haghighi N, et al. Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-alpha in myeloproliferative neoplasm. Blood Adv. 2019;3(2):122\u201331.","journal-title":"Blood Adv"},{"key":"774_CR13","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood-2021-154107","volume":"138","author":"A Fleischman","year":"2021","unstructured":"Fleischman A, Lai HY, Mehrota-Venkat N, Trieu T, Han T, Ramanathan G, et al. IL-10R Inhibition selects for Jak2V617F hematopoiesis by augmenting inflammation induced exhaustion of Wild-Type but not Jak2V617F hematopoietic stem cells. Blood. 2021;138:3595.","journal-title":"Blood"},{"issue":"1","key":"774_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canep.2013.10.009","volume":"38","author":"GJ Titmarsh","year":"2014","unstructured":"Titmarsh GJ, McMullin MF, McShane CM, Clarke M, Engels EA, Anderson LA. Community-acquired infections and their association with myeloid malignancies. Cancer Epidemiol. 2014;38(1):56\u201361.","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"774_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1365-2141.2007.06859.x","volume":"139","author":"O Landgren","year":"2007","unstructured":"Landgren O, Gridley G, Check D, Caporaso NE, Morris Brown L. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol. 2007;139(5):791\u20138.","journal-title":"Br J Haematol"},{"issue":"7","key":"774_CR16","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41416-024-02816-2","volume":"131","author":"E Packness","year":"2024","unstructured":"Packness E, Davidsson OB, Rostgaard K, Andersen MA, Rotbain EC, Niemann CU, et al. Infections and their prognostic significance before diagnosis of chronic lymphocytic leukemia, non-Hodgkin lymphoma, or multiple myeloma. Br J Cancer. 2024;131(7):1186\u201394.","journal-title":"Br J Cancer"},{"issue":"1","key":"774_CR17","first-page":"401","volume":"104","author":"YG Lee","year":"2025","unstructured":"Lee YG, Seo D, Gil HI, Koo DH, Oh SJ. Risk of malignant lymphoma in patients with previous tuberculosis infection: a cohort study. Ann Hematol. 2025;104(1):401\u20136.","journal-title":"Ann Hematol"},{"issue":"11","key":"774_CR18","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.1002\/cam4.1815","volume":"7","author":"KM Pedersen","year":"2018","unstructured":"Pedersen KM, Bak M, S\u00f8rensen AL, Zwisler AD, Ellervik C, Larsen MK, et al. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study. Cancer Med. 2018;7(11):5796\u2013802.","journal-title":"Cancer Med"},{"key":"774_CR19","doi-asserted-by":"publisher","first-page":"1210528","DOI":"10.3389\/fonc.2023.1210528","volume":"13","author":"G Ramanathan","year":"2023","unstructured":"Ramanathan G, Chen JH, Mehrotra N, Trieu T, Huang A, Mas E, et al. Cigarette smoke stimulates clonal expansion of Jak2(V617F) and Tet2(-\/-) cells. Front Oncol. 2023;13:1210528.","journal-title":"Front Oncol"},{"key":"774_CR20","doi-asserted-by":"crossref","unstructured":"Bhattacharya R, Zekavat SM, Uddin MM, Pirruccello J, Niroula A, Gibson C et al. Association of diet quality with prevalence of clonal hematopoiesis and adverse cardiovascular events. JAMA Cardiol. 2021;6(9):1069\u20131077.","DOI":"10.1001\/jamacardio.2021.1678"},{"key":"774_CR21","doi-asserted-by":"crossref","unstructured":"Pasupuleti SK, Ramdas B, Burns SS, Palam LR, Kanumuri R, Kumar R et al. Obesity-induced inflammation exacerbates clonal hematopoiesis. J Clin Investig. 2023;133(11):e163968.","DOI":"10.1172\/JCI163968"},{"issue":"3","key":"774_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41591-022-01708-3","volume":"28","author":"S Jasra","year":"2022","unstructured":"Jasra S, Giricz O, Zeig-Owens R, Pradhan K, Goldfarb DG, Barreto-Galvez A, et al. High burden of clonal hematopoiesis in first responders exposed to the world trade center disaster. Nat Med. 2022;28(3):468\u201371.","journal-title":"Nat Med"},{"key":"774_CR23","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.exphem.2023.06.046","volume":"124","author":"D Verma","year":"2023","unstructured":"Verma D, Giricz O, Zeig-Owens R, Pradhan K, Zou y, Goldfarb DD, et al. 2009 \u2013 World trade center 9\/11 Disaster exposure is associated with clonal hematopoiesis in first responders and is characterized by innate immune inflammation. Exp Hematol. 2023;124:S41.","journal-title":"Exp Hematol"},{"issue":"26","key":"774_CR24","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488\u201398.","journal-title":"N Engl J Med"},{"issue":"3","key":"774_CR25","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.stem.2021.02.001","volume":"28","author":"D Van Egeren","year":"2021","unstructured":"Van Egeren D, Escabi J, Nguyen M, Liu S, Reilly CR, Patel S, et al. Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms. Cell Stem Cell. 2021;28(3):514\u2013e239.","journal-title":"Cell Stem Cell"},{"issue":"7895","key":"774_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","volume":"602","author":"N Williams","year":"2022","unstructured":"Williams N, Lee J, Mitchell E, Moore L, Baxter EJ, Hewinson J, et al. Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature. 2022;602(7895):162\u20138.","journal-title":"Nature"},{"issue":"1","key":"774_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68\u201376.","journal-title":"Cancer"},{"issue":"10","key":"774_CR28","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncology: Official J Am Soc Clin Oncol. 2011;29(10):1356\u201363.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"9","key":"774_CR29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"3","key":"774_CR30","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1097\/HS9.0000000000000371","volume":"4","author":"NF \u00d8bro","year":"2020","unstructured":"\u00d8bro NF, Grinfeld J, Belmonte M, Irvine M, Shepherd MS, Rao TN, et al. Longitudinal cytokine profiling identifies GRO-\u03b1 and EGF as potential biomarkers of disease progression in essential thrombocythemia. HemaSphere. 2020;4(3):e371.","journal-title":"HemaSphere"},{"issue":"5","key":"774_CR31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia Vera. N Engl J Med. 2015;372(5):426\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"774_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3324\/haematol.2016.151126","volume":"102","author":"JO Mascarenhas","year":"2017","unstructured":"Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017;102(2):327\u201335.","journal-title":"Haematologica"},{"issue":"1","key":"774_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","volume":"15","author":"HT Chifotides","year":"2022","unstructured":"Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022;15(1):7.","journal-title":"J Hematol Oncol"},{"issue":"18","key":"774_CR34","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","volume":"4","author":"ST Oh","year":"2020","unstructured":"Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, et al. ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses Hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020;4(18):4282\u201391.","journal-title":"Blood Adv"},{"issue":"5","key":"774_CR35","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","volume":"31","author":"RK Rampal","year":"2025","unstructured":"Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, et al. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nat Med. 2025;31(5):1531\u20138.","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"774_CR36","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1182\/blood-2022-160409","volume":"140","author":"ST Oh","year":"2022","unstructured":"Oh ST, Verstovsek S, Gotlib J, Gupta V, Platzbecker U, Gisslinger H, et al. Bone marrow fibrosis changes do not correlate with efficacy outcomes in myelofibrosis: analysis of more than 300 JAK Inhibitor-Na\u00efve patients treated with momelotinib or ruxolitinib. Blood. 2022;140(Supplement 1):821\u20133.","journal-title":"Blood"},{"issue":"8","key":"774_CR37","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3324\/haematol.2019.226332","volume":"105","author":"F Kramer","year":"2020","unstructured":"Kramer F, Dernedde J, Mezheyeuski A, Tauber R, Micke P, Kappert K. Platelet-derived growth factor receptor \u03b2 activation and regulation in murine myelofibrosis. Haematologica. 2020;105(8):2083\u201394.","journal-title":"Haematologica"},{"key":"774_CR38","first-page":"5","volume":"3","author":"A Agarwal","year":"2016","unstructured":"Agarwal A, Morrone K, Bartenstein M, Zhao ZJ, Verma A, Goel S. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-\u03b2. Stem Cell Invest. 2016;3:5.","journal-title":"Stem Cell Invest"},{"issue":"18","key":"774_CR39","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood.2019004095","volume":"136","author":"HFE Gleitz","year":"2020","unstructured":"Gleitz HFE, Dugourd AJF, Leimk\u00fchler NB, Snoeren IAM, Fuchs SNR, Menzel S, et al. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood. 2020;136(18):2051\u201364.","journal-title":"Blood"},{"issue":"1","key":"774_CR40","doi-asserted-by":"publisher","first-page":"110189","DOI":"10.1016\/j.celrep.2021.110189","volume":"38","author":"AJ Affandi","year":"2022","unstructured":"Affandi AJ, Carvalheiro T, Ottria A, de Haan JJ, Brans MAD, Brandt MM, et al. CXCL4 drives fibrosis by promoting several key cellular and molecular processes. Cell Rep. 2022;38(1):110189.","journal-title":"Cell Rep"},{"key":"774_CR41","doi-asserted-by":"publisher","first-page":"1365015","DOI":"10.3389\/fimmu.2024.1365015","volume":"15","author":"G De Luca","year":"2024","unstructured":"De Luca G, Goette NP, Lev PR, Baroni Pietto MC, Marin Oyarz\u00fan CP, Castro R\u00edos MA, et al. Elevated levels of damage-associated molecular patterns HMGB1 and S100A8\/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis. Front Immunol. 2024;15:1365015.","journal-title":"Front Immunol"},{"issue":"5","key":"774_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s13402-018-0392-6","volume":"41","author":"M Kova\u010di\u0107","year":"2018","unstructured":"Kova\u010di\u0107 M, Mitrovi\u0107-Ajti\u0107 O, Beleslin-\u010coki\u0107 B, Djiki\u0107 D, Suboti\u010dki T, Dikli\u0107 M, et al. TLR4 and RAGE conversely mediate pro-inflammatory S100A8\/9-mediated Inhibition of proliferation-linked signaling in myeloproliferative neoplasms. Cell Oncol (Dordr). 2018;41(5):541\u201353.","journal-title":"Cell Oncol (Dordr)"},{"issue":"4","key":"774_CR43","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.stem.2020.11.004","volume":"28","author":"NB Leimk\u00fchler","year":"2021","unstructured":"Leimk\u00fchler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, et al. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2021;28(4):637\u2013e528.","journal-title":"Cell Stem Cell"},{"key":"774_CR44","doi-asserted-by":"crossref","unstructured":"Fiskus W, Masarova L, Mill CP, Birdwell C, Das K, Hou H et al. Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phase. Blood Adv. 2025;9(21):5598\u20135609.","DOI":"10.1182\/bloodadvances.2025016898"},{"key":"774_CR45","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.3389\/fimmu.2020.02093","volume":"11","author":"JS Jutzi","year":"2020","unstructured":"Jutzi JS, Mullally A. Remodeling the bone marrow Microenvironment - A proposal for targeting Pro-inflammatory contributors in MPN. Front Immunol. 2020;11:2093.","journal-title":"Front Immunol"},{"issue":"8","key":"774_CR46","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","volume":"4","author":"A Mullally","year":"2020","unstructured":"Mullally A, Hood J, Harrison C, Mesa R. Fedratinib in myelofibrosis. Blood Adv. 2020;4(8):1792\u2013800.","journal-title":"Blood Adv"},{"issue":"1","key":"774_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","volume":"35","author":"M Talpaz","year":"2021","unstructured":"Talpaz M, Kiladjian J-J. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia. 2021;35(1):1\u201317.","journal-title":"Leukemia"},{"issue":"11","key":"774_CR48","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.3324\/haematol.2022.282612","volume":"108","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Pardanani A, Gangat N. Momelotinib (JAK1\/JAK2\/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. Haematologica. 2023;108(11):2919\u201332.","journal-title":"Haematologica"},{"key":"774_CR49","doi-asserted-by":"publisher","unstructured":"Vachhani P, Mesa R, Mascarenhas J. JAK inhibitor selection in challenging scenarios of myelofibrosis: a review. Haematologica. 2025.\u00a0https:\/\/doi.org\/10.3324\/haematol.2025.288654.","DOI":"10.3324\/haematol.2025.288654"},{"issue":"4","key":"774_CR50","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino AV, Kanno Y, O\u2019Shea JJ. Mechanisms and consequences of Jak\u2013STAT signaling in the immune system. Nat Immunol. 2017;18(4):374\u201384.","journal-title":"Nat Immunol"},{"issue":"70","key":"774_CR51","doi-asserted-by":"publisher","first-page":"33416","DOI":"10.18632\/oncotarget.26058","volume":"9","author":"JW Singer","year":"2018","unstructured":"Singer JW, Fleischman A, Al-Fayoumi S, Mascarenhas JO, Yu Q, Agarwal A. Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget. 2018;9(70):33416\u201339.","journal-title":"Oncotarget"},{"key":"774_CR52","doi-asserted-by":"publisher","first-page":"117712","DOI":"10.1016\/j.biopha.2024.117712","volume":"181","author":"EJ Cuenca-Zamora","year":"2024","unstructured":"Cuenca-Zamora EJ, Mart\u00ednez C, Morales ML. Pacritinib prevents inflammation-driven myelofibrosis-like phenotype in a miR-146a murine model. Biomed Pharmacother. 2024;181:117712.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"774_CR53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33(1):29\u2013e437.","journal-title":"Cancer Cell"},{"issue":"1","key":"774_CR54","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"ZQ Wang","year":"2023","unstructured":"Wang ZQ, Zhang ZC, Wu YY, Pi YN, Lou SH, Liu TB, et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Signal Transduct Target Ther. 2023;8(1):420.","journal-title":"Signal Transduct Target Ther"},{"issue":"19","key":"774_CR55","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","volume":"7","author":"ST Oh","year":"2023","unstructured":"Oh ST, Mesa RA, Harrison CN. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023;7(19):5835\u201342.","journal-title":"Blood Adv"},{"issue":"13","key":"774_CR56","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","volume":"129","author":"M Asshoff","year":"2017","unstructured":"Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, et al. Momelotinib inhibits ACVR1\/ALK2, decreases Hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129(13):1823\u201330.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00774-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00774-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00774-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:04:42Z","timestamp":1772791482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00774-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["774"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00774-5","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}